AI Article Synopsis
- Digital polymerase chain reaction (dPCR) is a new molecular diagnostic method that offers enhanced sensitivity, precision, and specificity compared to traditional quantitative PCR (qPCR).
- Eight companies currently manufacture commercial dPCR instruments, including Fluidigm, Bio-Rad, and Qiagen, each with unique technical features and applications.
- The paper outlines the working principles of these devices, evaluates their usability and costs, and explores future developments in dPCR technology.
Article Abstract
Digital polymerase chain reaction (dPCR) technology has provided a new technique for molecular diagnostics, with superior advantages, such as higher sensitivity, precision, and specificity over quantitative real-time PCRs (qPCR). Eight companies have offered commercial dPCR instruments: Fluidigm Corporation, Bio-Rad, RainDance Technologies, Life Technologies, Qiagen, JN MedSys Clarity, Optolane, and Stilla Technologies Naica. This paper discusses the working principle of each offered dPCR device and compares the associated: technical aspects, usability, costs, and current applications of each dPCR device. Lastly, up-and-coming dPCR technologies are also presented, as anticipation of how the dPCR device landscape may likely morph in the next few years.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/07388551.2022.2037503 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!